The prevalence of PIK3CA mutations in this study cohort was in line with that reported in previous landmark studies using whole exome sequencing to analyze tumor-blood pairs obtained from patients with cervical cancer [7,8], suggesting that the analytical pipeline employed in the present study is robust. This evidence concerns the gene PIK3CA and cervical cancer.